OBJECTIVE: To investigate peripheral blood (PB) cell transcript profiles of systemic sclerosis (SSc) and its subtypes in direct comparison with systemic lupus erythematosus (SLE). METHODS: We investigated PB cell samples from 74 SSc patients, 21 healthy controls, and 17 SLE patients using Illumina Human Ref-8 BeadChips and quantitative polymerase chain reaction confirmation. None of the study participants were receiving immunosuppressive agents other than low-dose steroids and hydroxychloroquine. In addition to conventional statistical and modular analysis, a composite score for the interferon (IFN)-inducible genes was calculated. Within the group of patients with SSc, the correlation of the IFN score with the serologic and clinical subtypes was investigated, as were single-nucleotide polymorphisms in a selected number of IFN pathway genes. RESULTS: Many of the most prominently overexpressed genes in SSc and SLE were IFN-inducible genes. Forty-three of 47 overexpressed IFN-inducible genes in SSc (91%) were similarly altered in SLE. The IFN score was highest in the SLE patients, followed by the SSc patients, and then the controls. The difference in IFN score among all 3 groups was statistically significant (P < 0.001 for all 3 comparisons). SSc and SLE PB cell samples showed striking parallels to our previously reported SSc skin transcripts in regard to the IFN-inducible gene expression pattern. In SSc, the presence of antitopoisomerase and anti-U1 RNP antibodies and lymphopenia correlated with the higher IFN scores (P = 0.005, P = 0.001, and P = 0.004, respectively); a missense mutation in IFNAR2 was significantly associated with the IFN score. CONCLUSION: SLE and SSc fit within the same spectrum of IFN-mediated diseases. A subset of SSc patients shows a "lupus-like" high IFN-inducible gene expression pattern that correlates with the presence of antitopoisomerase and anti-U1 RNP antibodies.
OBJECTIVE: To investigate peripheral blood (PB) cell transcript profiles of systemic sclerosis (SSc) and its subtypes in direct comparison with systemic lupus erythematosus (SLE). METHODS: We investigated PB cell samples from 74 SSc patients, 21 healthy controls, and 17 SLEpatients using Illumina Human Ref-8 BeadChips and quantitative polymerase chain reaction confirmation. None of the study participants were receiving immunosuppressive agents other than low-dose steroids and hydroxychloroquine. In addition to conventional statistical and modular analysis, a composite score for the interferon (IFN)-inducible genes was calculated. Within the group of patients with SSc, the correlation of the IFN score with the serologic and clinical subtypes was investigated, as were single-nucleotide polymorphisms in a selected number of IFN pathway genes. RESULTS: Many of the most prominently overexpressed genes in SSc and SLE were IFN-inducible genes. Forty-three of 47 overexpressed IFN-inducible genes in SSc (91%) were similarly altered in SLE. The IFN score was highest in the SLEpatients, followed by the SSc patients, and then the controls. The difference in IFN score among all 3 groups was statistically significant (P < 0.001 for all 3 comparisons). SSc and SLE PB cell samples showed striking parallels to our previously reported SSc skin transcripts in regard to the IFN-inducible gene expression pattern. In SSc, the presence of antitopoisomerase and anti-U1 RNP antibodies and lymphopenia correlated with the higher IFN scores (P = 0.005, P = 0.001, and P = 0.004, respectively); a missense mutation in IFNAR2 was significantly associated with the IFN score. CONCLUSION:SLE and SSc fit within the same spectrum of IFN-mediated diseases. A subset of SSc patients shows a "lupus-like" high IFN-inducible gene expression pattern that correlates with the presence of antitopoisomerase and anti-U1 RNP antibodies.
Authors: F P Siegal; N Kadowaki; M Shodell; P A Fitzgerald-Bocarsly; K Shah; S Ho; S Antonenko; Y J Liu Journal: Science Date: 1999-06-11 Impact factor: 47.728
Authors: Pravitt Gourh; Filemon K Tan; Shervin Assassi; Chul W Ahn; Terry A McNearney; Michael Fischbach; Frank C Arnett; Maureen D Mayes Journal: Arthritis Rheum Date: 2006-12
Authors: Humphrey Gardner; Jeffrey R Shearstone; Raj Bandaru; Tom Crowell; Matthew Lynes; Maria Trojanowska; Jaspreet Pannu; Edwin Smith; Stefania Jablonska; Maria Blaszczyk; Filemon K Tan; Maureen D Mayes Journal: Arthritis Rheum Date: 2006-06
Authors: Lindsey A Criswell; Kirsten A Pfeiffer; Raymond F Lum; Bonnie Gonzales; Jill Novitzke; Marlena Kern; Kathy L Moser; Ann B Begovich; Victoria E H Carlton; Wentian Li; Annette T Lee; Ward Ortmann; Timothy W Behrens; Peter K Gregersen Journal: Am J Hum Genet Date: 2005-02-17 Impact factor: 11.025
Authors: Michael R York; Taro Nagai; Alyson J Mangini; Raphaël Lemaire; Jean Maguire van Seventer; Robert Lafyatis Journal: Arthritis Rheum Date: 2007-03
Authors: Hangjun Duan; Jo Fleming; David K Pritchard; Lynn M Amon; Jun Xue; Heather A Arnett; Guang Chen; Patricia Breen; Jane H Buckner; Jerry A Molitor; Keith B Elkon; Stephen M Schwartz Journal: Arthritis Rheum Date: 2008-05
Authors: Alexander M S Barron; Julio C Mantero; Jonathan D Ho; Banafsheh Nazari; Katharine L Horback; Jag Bhawan; Robert Lafyatis; Christina Lam; Jeffrey L Browning Journal: J Immunol Date: 2018-12-03 Impact factor: 5.422
Authors: David R Gibb; Jingchun Liu; Prabitha Natarajan; Manjula Santhanakrishnan; David J Madrid; Stephanie C Eisenbarth; James C Zimring; Akiko Iwasaki; Jeanne E Hendrickson Journal: J Immunol Date: 2017-06-19 Impact factor: 5.422
Authors: Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress Journal: J Immunol Date: 2016-09-30 Impact factor: 5.422